Browse > Article

Association Study between Treatment Response of Amisulpride and Dopamine D3 Receptor Gene Polymorphisms  

Kang, Seung-Gul (Department of Psychiatry, Gil Medical Center, Gachon University School of Medicine)
Lee, Heon-Jeong (Department of Psychiatry, Korea University College of Medicine)
Lee, Seung Jae (Department of Psychiatry, Kyungpook National University School of Medicine)
Choi, Tae Young (Department of Psychiatry, Catholic University of Daegu School of Medicine)
Woo, Jungmin (Department of Psychiatry, Catholic University of Daegu School of Medicine)
Kim, Jihyun (Department of Psychiatry, Catholic University of Daegu School of Medicine)
Jung, Sung-Won (Department of Psychiatry, Dongsan Medical Center, Keimyung University School of Medicine)
Koo, Bon Hoon (Department of Psychiatry, College of Medicine, Yeungnam University)
Lee, Kwanghun (Department of Psychiatry, Dongguk University College of Medicine)
Kim, Jeong-Lan (Department of Psychiatry, School of Medicine, Chungnam National University)
Chee, Ik-Seung (Department of Psychiatry, School of Medicine, Chungnam National University)
Lee, Jonghun (Department of Psychiatry, Catholic University of Daegu School of Medicine)
Publication Information
Korean Journal of Biological Psychiatry / v.20, no.3, 2013 , pp. 91-96 More about this Journal
Abstract
Objectives The aim of this study is to evaluate the association between rs6280 and rs905568 genetic polymorphism of DRD3 gene and the treatment response of amisulpride. Methods After six weeks treatment of amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity (CGI-S). The genotyping for rs6280 and rs905568 was performed using TaqMan single nucleotide polymorphism (SNP) genotyping assay. Results There was no significant difference in the frequency of genotype and allele of rs6280 between the responders and non-responders based on the total, positive, and general score of PANSS and CGI-S score. However, there was a significant association between this SNP and treatment response in the negative score of PANSS (${\chi}^2=5.23$, p = 0.022). There was no significant association between rs905568 and the response in positive, negative, general, and total PANSS score and CGI-S score. Conclusions This is the first positive association study between DRD3 gene and the treatment response of negative symptoms to amisulpride in Korean schizophrenia patients. A larger scale research on more SNP of the DRD3 gene will make a progress in the study of pharmacogenetics on the treatment response of the amisulpride.
Keywords
Treatment response; Amisulpride; DRD3 gene; Polymorphisms; rs6280;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Moller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl) 1997; 132:396-401.   DOI
2 Puech A, Fleurot O, Rein W. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 1998;98:65-72.   DOI
3 Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-190.   DOI
4 Mortimer A, Martin S, LÔo H, Peuskens J; SOLIANOL Sudy Group. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004;19:63-69.   DOI
5 Peuskens J, Bech P, MÖller HJ, Bale R, Fleurot O, Rein W. Amisul- pride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 1999;88:107- 117.   DOI
6 Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-1097.   DOI
7 Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000;15:13-22.   DOI
8 Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146-151.   DOI
9 Sokoloff P, Martres MP, Giros B, Bouthenet ML, Schwartz JC. The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol 1992;43:659-666.   DOI
10 Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, Lucotte G, et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A 2006;103:10753-10758.   DOI
11 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text-Revision. Washington DC: American Psychiatric Publishing, Inc.;2000.
12 Jonsson EG, Flyckt L, Burgert E, Crocq MA, Forslund K, Mattila-Evenden M, et al. Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr Genet 2003;13:1-12.   DOI
13 Hwang R, Zai C, Tiwari A, Muller DJ, Arranz MJ, Morris AG, et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 2010;10: 200-218.   DOI
14 Zai CC, Tiwari AK, De Luca V, Müller DJ, Bulgin N, Hwang R, et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009;19:317-328.   DOI
15 Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
16 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.   DOI
17 Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 2005;10:917-925.   DOI
18 Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005;25:6-11.   DOI
19 Kim B, Choi EY, Kim CY, Song K, Joo YH. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol 2008; 23:61-67.   DOI
20 Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996;225:1068-1072.   DOI
21 Shaikh S, Collier DA, Sham PC, Ball D, Aitchison K, Vallada H, et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 1996;97:714- 719.   DOI
22 Xuan J, Zhao X, He G, Yu L, Wang L, Tang W, et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology 2008; 33:305-311.   DOI
23 Chen SF, Shen YC, Chen CH. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:470-474.   DOI
24 Kim HC, Jung SW, Kim DK. The relationship between the antipsychotics- induced weight gain and the dopamine D2, D3, and D4 receptor gene polymorphisms in Korean. Korean J Psychopharmacol 2007;18:299-307.